Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naess, H.
Right arrow Articles by Myhr, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naess, H.
Right arrow Articles by Myhr, K. M.
Related Collections
Right arrow Stroke prevention
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
Right arrowRelated Article
NEUROLOGY 2005;65:609-611
© 2005 American Academy of Neurology
Brief Communications

Do all young ischemic stroke patients need long-term secondary preventive medication?

H. Naess, MD, PhD, U. Waje-Andreassen, MD, L. Thomassen, MD, H. Nyland, MD, PhD and K. M. Myhr, MD, PhD

From Department of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway.

Address correspondence and reprint requests to Dr. Halvor Naess, Department of Neurology, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway; e-mail: halvor.naess{at}haukeland.no

After a mean of 6 years, the frequencies of later vascular events (recurrent ischemic stroke or myocardial infarction) in 232 young ischemic stroke patients (younger than 50 years) with none to five traditional risk factors were 2.1%, 6%, 19%, 26%, 30%, and 67% (p < 0.001). Long-term secondary preventive medication may not be indicated in young ischemic stroke patients with no risk factor.

Disclosure: The authors report no conflicts of interest.

Received January 11, 2005. Accepted in final form April 18, 2005.


Related Article

August 23 Highlights
Neurology 2005 65: 504-505. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BMJHome page
Minerva
BMJ, December 17, 2005; 331(7530): E398 - E398.
[Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, September 10, 2005; 331(7516): 584 - 584.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.